---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-051823"
form_type: "8-K/A"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2022-08-29T23:59:59+00:00"
generated_at: "2026-06-23T20:28:39.284459+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022

## Summary
- Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.
- Q1 2022 net loss was $447k; accumulated deficit reached $2.15M as of March 31, 2022.
- Total assets $200k, cash & equivalents $122k at March 31, 2022, down from $295k at year-end 2021.
- Acquisition closed June 21, 2022; one seller is Pasithea's Executive Chairman and Co-Founder.
- Pro forma adjustments deemed immaterial; Alpha-5 became a wholly owned subsidiary of Pasithea.

## SEC filing metadata
- accession: 0001213900-22-051823
- form_type: 8-K/A
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2022-08-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390022051823/0001213900-22-051823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390022051823/ea165047-8ka2_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-051823
- JSON: https://secwatch.observer/filing/0001213900-22-051823.json
- Plain text: https://secwatch.observer/filing/0001213900-22-051823.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.